GLENMARK PHARMACEUTICALS LTD. - 532296 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the year ended 31st March, 202017-07-2020
17-07-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- HARISH KUBERDesignation :- Company Secretary and Compliance Officer14-07-2020
Coronavirus drug: Biophore India gets DCGI nod to manufacture Favipiravir
Biophore is also awaiting DCGI approval for Favipiravir's finished dosage form; apart from Biophore, Glenmark has also launched antiviral drug of Favipiravir, named as FabiFlu, for the treatment of mild to moderate COVID-19 patients14-07-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark commences 1000 patients Post Marketing Surveillance study with COVID-19 who are administered FabiFlu(r) Also, due to better yield and scale, Glenmark passes the benefits to patients by reducing the price of oral antiviral FabiFlu(r) by 27 % in India13-07-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Credit Rating
Glenmark would like to inform you that Fitch Ratings, as part of their annual review cycle, has reaffirmed the Company's credit rating at 'BB', outlook 'stable'. This credit rating assigned to Glenmark is much higher than some of its global peers as mentioned in the enclosed report. The agency also affirmed the rating on Company's USD200 million 4.50% senior unsecured notes issued in 2016 at ''BB''.11-07-2020
Is the Covid-19 drug good news for Glenmark Pharmaceuticals?
Favipiravir's potential is unclear; challengesin the US business need a watch05-07-2020
Sell Glenmark Pharmaceuticals; target of Rs 365: Prabhudas Lilladher
Prabhudas Lilladher is bearish on Glenmark Pharmaceuticals has recommended sell rating on the stock with a target price of Rs 365 in its research report dated June 29, 2020.02-07-2020
US charges Glenmark Pharma with conspiracy in price fixing
Glenmark allegedly conspired with pharmaceutical company Apotex Corp and other generic drug companies to increase prices of cholesterol medication pravastatin and other generic drugs01-07-2020
Glenmark's Q4 shows decent progress, but managing cash flows critical
Its US business is weak, with revenues sliding 1%.In dermatology, prices have contracted about 20%29-06-2020
Earnings Call Transcript - Q4FY20 for Glenmark Pharmaceuticals
Conference Call with Glenmark Pharmaceuticals Management and Analysts on Q4FY20 and Full Year Earnings Performance and Outlook. Listen to the full earnings transcript. Key Highlights from Management Our growth momentum sustained in the Fourth Quarter despite the COVID-19 pandemic and challenging generic business environment across markets globally. Our India, Europe and Latin America regions performed well during the quarter. Our sustained performance has been due to the continuous efforts of all our employees around the world. Our manufacturing facilities have operated continuously and facilitated the uninterrupted supply of medicines to operating markets For the Fourth Quarter of FY 2019-20, Glenmark’s consolidated revenue was at Rs. 27,674.89 Mn. as against Rs. 25,634.74 Mn. recording an increase of 7.96 %. Consolidated Net Profit was at Rs. 2203.08 Mn. for the quarter ended March 31, 2019 as compared to Rs. 1,616.62 Mn. in the previous corresponding quarter, registering an increase of 36.28%. Consolidated EBITDA grew by 27.89% to Rs. 4656.87 Mn. in the quarter ended March 31, 2020 as against Rs. 3,641.31 Mn. in the previous corresponding quarter. For the year ended March 31, 2020, Glenmark’s consolidated revenue was at Rs. 106,409.69 Mn as against Rs. 98,654.69 Mn., recording an increase of 7.86% over the previous corresponding period. Consolidated Net Profit was at Rs. 7759.70 Mn. for the year ended March 31, 2020, as against Rs. 9,249.93 Mn. in the previous year. Consolidated EBITDA for the fiscal year ended March 31, 2020 stood at Rs. 16980.82 Mn. as against Rs. 15,857.99 Mn. in the previous corresponding period. India Sales from the formulation business in India for the Fourth Quarter of FY 2019-20 was at Rs. 7,647.53 Mn as against Rs. 6677.94 Mn in the previous corresponding quarter, recording growth of 14.52 %. Glenmark Consumer Care Business Glenmark Consumer Care business continued to maintain strong growth momentum of 31 % in the quarter of this financial year and the business setting a new milestone of sales of INR 203.8 crore in this financial year. USA Glenmark Pharmaceuticals Inc USA registered revenue from the sale of finished dosage formulations of Rs. 7,619.02 Mn for the quarter ended March 31, 2020 as against revenue of Rs. 7696 Mn for the previous corresponding quarter, recording a de-growth of (1 %) Africa, Asia and CIS Region (ROW) For the Fourth Quarter of FY 2019-20, revenue from Africa, Asia and CIS region was Rs. 3365.47 Mn as against Rs. 3852.85 Mn for the previous corresponding quarter, recording de-growth of (12.65 %) Europe Glenmark Europe’s operations revenue for the Fourth Quarter of FY 2019-20 was at Rs. 4115.68 Mn as against Rs. 3184.07 Mn recording a growth of 29.26 %. Latin America Glenmark’s revenue from its Latin American and Caribbean operations was at Rs. 1768.73 Mn for the Fourth Quarter of FY 2019-20, as against Rs. 1204.07 Mn., recording an increase of 46.9 %. API Business For the Fourth Quarter of FY 2019-20, external sales for Glenmark Life Sciences was at Rs. 2613.79 Mn as against Rs. 2487.77 Mn., recording growth of 5.07 % over the corresponding period last year. For the entire year, external sales of Glenmark Life Sciences recorded revenue of INR. 10239.17 Mn as against Rs. 9493.11 Mn. in the previous financial year, recording growth of 7.86 % over the corresponding period last year.29-06-2020